BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 16239967)

  • 1. Treatment of murine Th1- and Th2-mediated inflammatory bowel disease with NF-kappa B decoy oligonucleotides.
    Fichtner-Feigl S; Fuss IJ; Preiss JC; Strober W; Kitani A
    J Clin Invest; 2005 Nov; 115(11):3057-71. PubMed ID: 16239967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-viral delivery of nuclear factor-kappaB decoy ameliorates murine inflammatory bowel disease and restores tissue homeostasis.
    De Vry CG; Prasad S; Komuves L; Lorenzana C; Parham C; Le T; Adda S; Hoffman J; Kahoud N; Garlapati R; Shyamsundar R; Mai K; Zhang J; Muchamuel T; Dajee M; Schryver B; McEvoy LM; Ehrhardt RO
    Gut; 2007 Apr; 56(4):524-33. PubMed ID: 16950831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of decoy oligodeoxynucleotides targeted to NF-kappaB in vitro and in vivo.
    Wang T; Li QH; Hao GP; Zhai J
    Asian Pac J Cancer Prev; 2010; 11(1):193-200. PubMed ID: 20593956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of intratracheal administration of nuclear factor-kappaB decoy oligodeoxynucleotides on long-term cigarette smoke-induced lung inflammation and pathology in mice.
    Li YT; He B; Wang YZ; Wang J
    Respir Res; 2009 Aug; 10(1):79. PubMed ID: 19706153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The inhibitory effects of dumb-bell decoy oligodeoxynucleotides targeting NF-kappaB on the growth of multiple myeloma cells and IL-6 expression].
    Jiang HL; Xue WJ; Liu H; Chen W
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2006 Jan; 22(1):47-50. PubMed ID: 16388744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amelioration of murine dextran sulfate sodium-induced colitis by nuclear factor-kappaB decoy oligonucleotides.
    Xiang JY; Wu LG; Huang XL; Zhang M; Pen L; Ouyan Q; Gan HT
    Am J Surg; 2009 Jun; 197(6):797-805. PubMed ID: 18926515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic effect of ribbon-type nuclear factor-κB decoy oligonucleotides in a rat model of inflammatory bowel disease.
    Ozaki K; Makino H; Aoki M; Miyake T; Yasumasa N; Osako MK; Nakagami H; Rakugi H; Morishita R
    Curr Gene Ther; 2012 Dec; 12(6):484-92. PubMed ID: 23061565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppressive oligodeoxynucleotides inhibit atherosclerosis in ApoE(-/-) mice through modulation of Th1/Th2 balance.
    Cheng X; Chen Y; Xie JJ; Yao R; Yu X; Liao MY; Ding YJ; Tang TT; Liao YH; Cheng Y
    J Mol Cell Cardiol; 2008 Aug; 45(2):168-75. PubMed ID: 18502445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity of NF-kB decoy oligodeoxynucleotides in a prostate cancer cell line.
    Fang Y; Sun H; Zhai J; Zhang Y; Yi S; Hao G; Wang T
    Asian Pac J Cancer Prev; 2011; 12(10):2721-6. PubMed ID: 22320981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decoy oligodeoxyribonucleotides and peptide nucleic acids-DNA chimeras targeting nuclear factor kappa-B: inhibition of IL-8 gene expression in cystic fibrosis cells infected with Pseudomonas aeruginosa.
    Gambari R; Borgatti M; Bezzerri V; Nicolis E; Lampronti I; Dechecchi MC; Mancini I; Tamanini A; Cabrini G
    Biochem Pharmacol; 2010 Dec; 80(12):1887-94. PubMed ID: 20615393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcriptional regulation of NF-kappaB by ring type decoy oligodeoxynucleotide in an animal model of nephropathy.
    Kim KH; Lee ES; Cha SH; Park JH; Park JS; Chang YC; Park KK
    Exp Mol Pathol; 2009 Apr; 86(2):114-20. PubMed ID: 19118545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A role for NF-kappaB-dependent gene transactivation in sunburn.
    Abeyama K; Eng W; Jester JV; Vink AA; Edelbaum D; Cockerell CJ; Bergstresser PR; Takashima A
    J Clin Invest; 2000 Jun; 105(12):1751-9. PubMed ID: 10862790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-(3', 4'-dimethoxycinnamonyl) anthranilic acid alleviated experimental colitis by inhibiting autoimmune response and inducing CD4+ CD25+ regulatory T cells production.
    Wen Q; Zhou L; Chen H; Zhang Y
    J Gastroenterol Hepatol; 2013 Aug; 28(8):1330-8. PubMed ID: 23663055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of non-antibiotic macrolide that corrects inflammation-driven immune dysfunction in models of inflammatory bowel diseases and arthritis.
    Mencarelli A; Distrutti E; Renga B; Cipriani S; Palladino G; Booth C; Tudor G; Guse JH; Hahn U; Burnet M; Fiorucci S
    Eur J Pharmacol; 2011 Aug; 665(1-3):29-39. PubMed ID: 21554873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nuclear factor kappa B decoy oligodeoxynucleotides prevent endotoxin-induced fatal liver failure in a murine model.
    Ogushi I; Iimuro Y; Seki E; Son G; Hirano T; Hada T; Tsutsui H; Nakanishi K; Morishita R; Kaneda Y; Fujimoto J
    Hepatology; 2003 Aug; 38(2):335-44. PubMed ID: 12883477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of recombinant Trichinella spiralis cysteine proteinase inhibitor on TNBS-induced experimental inflammatory bowel disease in mice.
    Xu J; Liu M; Yu P; Wu L; Lu Y
    Int Immunopharmacol; 2019 Jan; 66():28-40. PubMed ID: 30419451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Andrographolide sulfonate ameliorates experimental colitis in mice by inhibiting Th1/Th17 response.
    Liu W; Guo W; Guo L; Gu Y; Cai P; Xie N; Yang X; Shu Y; Wu X; Sun Y; Xu Q
    Int Immunopharmacol; 2014 Jun; 20(2):337-45. PubMed ID: 24704625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carboxyamidotriazole ameliorates experimental colitis by inhibition of cytokine production, nuclear factor-κB activation, and colonic fibrosis.
    Guo L; Ye C; Hao X; Zheng R; Ju R; Wu D; Luo L; Wang C; Li J; Yu X; Zhu L; Zhang D
    J Pharmacol Exp Ther; 2012 Aug; 342(2):356-65. PubMed ID: 22553216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucocorticoid-induced leucine zipper is protective in Th1-mediated models of colitis.
    Cannarile L; Cuzzocrea S; Santucci L; Agostini M; Mazzon E; Esposito E; Muià C; Coppo M; Di Paola R; Riccardi C
    Gastroenterology; 2009 Feb; 136(2):530-41. PubMed ID: 18996377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of inflammatory bowel disease.
    Lee J; Lee EN; Kim EY; Park HJ; Chang CY; Jung DY; Choi SY; Lee SK; Lee KW; Kwon GY; Joh JW; Kim SJ
    Immunol Lett; 2005 Nov; 101(2):210-6. PubMed ID: 16026855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.